Cortisporin TC colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate 3 mg/mL; 3.3 mg/mL; .5 mg/mL; 10 mg/mL Suspension, 10 mL — NDC 63481-0529-10 package photo

Cortisporin TC colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate 3 mg/mL; 3.3 mg/mL; .5 mg/mL; 10 mg/mL Suspension, 10 mL

by Endo USA, Inc. · 10 mL in 1 BOTTLE, DROPPER (63481-529-10)
NDC 63481-0529-10
🏷️ FDA NDC (as labeled) 63481-529-10 billing pads the product segment with a zero
Rx only Brand On market Non-controlled
🗂️ Data synced Aug 27, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 63481-529-10
Product NDC 63481-529
11-digit billing NDC 63481052910
NCPDP billing unit ML — per mL (volume)
RxCUI 854992, 854997
UNII WP15DXU577, 057Y626693, JI2B19CR0R, 3X7931PO74
Application # NDA050356
SPL Set ID 9c6fc1c7-3350-42ae-b999-aca48e704bb1
Established class (EPC) Aminoglycoside Antibacterial; Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
Chemical class Aminoglycosides
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2019-06-03
Route AURICULAR (OTIC)
Dosage form SUSPENSION
Substance COLISTIN SULFATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE; HYDROCORTISONE ACETATE
GPI-14 87991004201820
GPI class Cortisporin-TC
GCN Seq No 048618
GCN 14106
HICL code 018381
Ingredient (HICL) Neomyc/Colist/Hydrocort/Thonzn
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q8
Therapeutic class — intermediate (HIC2) Otic Preparations
HIC3 code Q8W
Therapeutic class — specific (HIC3) Ear Preparations,Antibiotics
AHFS code 52:04.04.00
AHFS class Antibacterials (52:04)
FDB label name CORTISPORIN-TC EAR SUSPENSION
FDB brand name Cortisporin-Tc
Legend status F — Federal legend — prescription drug or device
Why two NDCs? The FDA registers this code as 63481-529-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 63481-0529-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏭 Manufacturer & labeler

LabelerEndo USA, Inc.
Application holderPH HEALTH LTD
FDA applicationNDA050356 (NDA)
Labeler code63481
First marketedJun 2019
Product typeHuman Prescription Drug
Portfolio101 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name CORTISPORIN-TC EAR SUSPENSION Ingredient Neomyc/Colist/Hydrocort/Thonzn
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII Q40Q9N063P
    Acetic acid is a weak organic acid commonly used in medicines as a buffer and pH adjuster. It helps maintain the proper acidity level to ensure the drug remains stable and effective in its formulation.
  • UNII 6OZP39ZG8H
    Polysorbate 80 is a synthetic emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together in medications and improves how the product disperses in the body.
  • UNII 4550K0SC9B
    Sodium acetate is a salt derived from acetic acid. It acts as a buffer to help maintain the medicine's pH stability and may serve as a preservative or solubilizer in liquid formulations.
  • UNII 2225PI3MOV
    A mercury-containing preservative used to prevent bacterial and fungal contamination in multi-dose vials of vaccines and some injectable medicines. It stops microorganisms from growing in the product during storage and use.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $21.986 $219.86 / 10 ml
Medicaid paysCMS SDUD · 12 mo $22.97 $229.71 / 10 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2021 Jan 2026 Apr 2026 Aug 2026 $22.302 $21.986
▼ Down 1% over the last 11 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Cortisporin TC 3 mg/mL; 3.3 mg/mL; .5 mg/mL; 10 mg/mLthis 63481-0529-10 Endo 10 ml $21.986 Availability likely
About this product: this is the brand-name version. We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2019
On the market since
Jun 2019
📍
2026
Currently FDA-listed
7 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 63481-0529-10, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
7.5K
Units reimbursed last 4 qtrs
77.1K
Gross reimbursed last 4 qtrs
$1.77M
Avg / prescription
$235.43
Avg / unit
$22.9713
Latest quarter Q4 2025
1.5KRx
Medicaid pays / mL
$22.9713
gross reimbursed
vs
NADAC / mL
$21.9856
acquisition cost
=
Spread
+$0.9857
+4% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
81% FFS 19% MCO
Fee-for-service · 6,091 Rx Managed care · 1,429 Rx
State Medicaid map
Alaska: no data reported AK Maine: 935 units · 67.0 per 100k residents ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: 180 units · 3.0 per 100k residents WI Michigan: 110 units · 1.1 per 100k residents MI New York: 16,445 units · 84.0 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 120 units · 2.8 per 100k residents OR Nevada: 220 units · 6.9 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 2,560 units · 37.3 per 100k residents IN Ohio: 3,490 units · 29.6 per 100k residents OH Pennsylvania: 220 units · 1.7 per 100k residents PA New Jersey: no data reported NJ Massachusetts: 3,260 units · 46.6 per 100k residents MA California: 35,280 units · 90.5 per 100k residents CA Utah: no data reported UT Colorado: 900 units · 15.3 per 100k residents CO Nebraska: no data reported NE Missouri: 1,900 units · 30.7 per 100k residents MO Kentucky: 311 units · 6.9 per 100k residents KY West Virginia: 930 units · 52.5 per 100k residents WV Virginia: 110 units · 1.3 per 100k residents VA Maryland: no data reported MD Connecticut: 560 units · 15.5 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 2,090 units · 29.3 per 100k residents TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: 640 units · 62.1 per 100k residents DE Oklahoma: 2,500 units · 61.7 per 100k residents OK Louisiana: 130 units · 2.8 per 100k residents LA Mississippi: 1,150 units · 39.1 per 100k residents MS Alabama: no data reported AL Georgia: 850 units · 7.7 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 1,700 units · 5.6 per 100k residents TX Florida: 480 units · 2.1 per 100k residents FL
Units reimbursed · per 100k residents
1.190.5
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 California 90.5 /100k
2 New York 84.0 /100k
3 Maine 67.0 /100k
4 Delaware 62.1 /100k
5 Oklahoma 61.7 /100k
6 West Virginia 52.5 /100k
7 Massachusetts 46.6 /100k
8 Mississippi 39.1 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Cortisporin-Tc — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Cortisporin-Tc. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$330.9K
Claims incl. refills
1.4K
Beneficiaries
1.3K
Spend / beneficiary
$248.59
Spend / claim
$236.34
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Cortisporin TC (this brand).

Top reported reactions

Asthenia1
Central Nervous System Lymphoma1
Colitis1
Dehydration1
Diarrhoea1
Dizziness Postural1
Dysstasia1

Age at onset

Elderly1

Reporter sex

2 reports
Male · 50%
Female · 50%

Serious outcomes

Hospitalization2
Reports over time (by year) — tap or hover for the count & year
2022 2023 2024 2026 1 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
63481-0529-10 You're viewing this 10 mL in 1 BOTTLE, DROPPER (63481-529-10) 2019-06-03 Active

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 49 words

INDICATIONS AND USAGE Cortisporin ® TC Otic is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics.

⏱️ Dosage and Administration 157 words

DOSAGE AND ADMINISTRATION Therapy with this product should be limited to 10 days (See WARNINGS ). The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. When using the calibrated dropper: For adults, 5 drops of the suspension should be instilled into the affected ear 3 or 4 times daily.

For pediatric patients, 4 drops are suggested because of the smaller capacity of the ear canal. The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal.

Repeat, if necessary, for the opposite ear. If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the suspension. This wick should be kept moist by adding further solution every 4 hours.

The wick should be replaced at least once every 24 hours.

Contraindications 48 words

CONTRAINDICATIONS This product is contraindicated in those individuals who have shown hypersensitivity to any of its components. This product should not be used if the external auditory canal disorder is suspected or known to be due to cutaneous viral infection (e.g., herpes simplex virus or varicella zoster virus).

⚠️ Warnings 211 words

WARNINGS Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days (See PRECAUTIONS-General ).

Patients being treated with eardrops containing neomycin should be under close clinical observation. Cortisporin ® TC Otic should be used cautiously in any patient with a perforated tympanic membrane. Neomycin sulfate may cause cutaneous sensitization.

A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known. Discontinue promptly if sensitivity or irritation occurs. When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin.

The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication.

Neomycin containing applications should be avoided for the patient thereafter.

🤒 Adverse Reactions 149 words

ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity (see WARNINGS section) and nephrotoxicity have also been reported. Adverse reactions have occurred with topical use of antibiotic combinations.

Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.

In another study the incidence was found to be approximately 1%. The following local adverse events have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. For medical advice about adverse reactions contact your medical professional.

To report SUSPECTED ADVERSE REACTIONS, contact Endo at 1-800-462-3636 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🤰 Pregnancy ~1 min read

Pregnancy Teratogenic Effects Pregnancy Category C There are no adequate and well controlled studies of Cortisporin ® TC Otic in pregnant women. It is not known whether Cortisporin ® TC Otic can cause fetal harm when administered to a pregnant woman. Colistimethate sodium, the methanesulfonate salt of colistin, was not teratogenic in rats or rabbits given intramuscular doses up to 20 mg/kg (equivalent to 9.3 mg/kg of colisitin base, approximately 30 times (rats) or 55 times (rabbits) the clinical daily dose based on body surface area and assuming 100% absorption from the ear).

Increased resorptions were observed in rabbits at 20 mg/kg, but not 10 mg/kg (equivalent to 4.15 mg/kg of colistin base). Decreased pup survival at weaning was observed in rats at 20 mg/kg, a maternally toxic dose of colistin, but not 10 mg/kg. Colistin has not been shown to have any adverse effects on the developing embryo or fetus at doses relevant to the amount that will be delivered ototopically at the recommended clinical doses.

Although aminoglycosides can cause congenital deafness in humans if administered during pregnancy, significant systemic levels of neomycin would not be anticipated when Cortisporin ® TC Otic is used as directed. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.

Cortisporin ® TC Otic should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

🧒 Pediatric Use 72 words

Pediatric Use See DOSAGE AND ADMINISTRATION . The safety and effectiveness of Cortisporin ® TC Otic in infants below one year of age have not been established. The efficacy of Cortisporin ® TC Otic in pediatric patients one year or older in the treatment of superficial bacterial infections of the external auditory canal and for the treatment of infections of mastoidectomy and fenestration cavities has been demonstrated in a controlled clinical trial.

🧓 Geriatric Use 17 words

Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.

🧬 Clinical Pharmacology 211 words

CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a corticosteroid hormone which is thought to act by regulating the rate of protein synthesis; it controls inflammation, edema, pruritus and other dermal reactions.

Corticosteroids suppress the inflammatory response to a variety of agents and they may delay healing. Since corticoids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case. The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle.

Thonzonium bromide is a surface-active agent that promotes tissue contact by dispersion and penetration of the cellular debris and exudate. Microbiology Together, colistin sulfate and neomycin sulfate have bactericidal activity against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Aerobic gram-positive microorganisms: Staphylococcus aureus.

Aerobic gram-negative microorganisms: Enterobacter aerogenes Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa. Susceptibility Tests: It is not recommended that colistin sulfate or neomycin sulfate be routinely tested and reported by clinical microbiology laboratories.

📦 How Supplied / Storage and Handling 101 words

HOW SUPPLIED Cortisporin ® TC Otic is supplied as: NDC 63481-529-10 10 mL bottle with dropper Each mL contains: Colistin sulfate equivalent to 3 mg of colistin base activity, Neomycin sulfate equivalent to 3.3 mg neomycin base activity, Hydrocortisone acetate 10 mg (1%), Thonzonium bromide 0.5 mg (0.05%), and Polysorbate 80 in an aqueous vehicle buffered with acetic acid and sodium acetate. Thimerosal (mercury derivative) 0.002% is added as a preservative. A sterilized dropper-cap assembly for use on the bottle of suspension is included in the package.

Shake well before using. Store at 20° to 25°C (68° to 77°F). Rx only.

📦 Storage and Handling 10 words

Store at 20° to 25°C (68° to 77°F). Rx only.

📋 Description 160 words

DESCRIPTION Cortisporin ® TC Otic with Neomycin and Hydrocortisone (colistin sulfate—neomycin sulfate—thonzonium bromide—hydrocortisone acetate otic suspension) is a sterile antibacterial and anti-inflammatory aqueous suspension containing in each mL: Colistin base activity, 3 mg (as the sulfate); Neomycin base activity, 3.3 mg (as the sulfate); Hydrocortisone acetate, 10 mg (1%); Thonzonium bromide, 0.5 mg (0.05%); Polysorbate 80, acetic acid, and sodium acetate in a buffered aqueous vehicle. Thimerosal (mercury derivative), 0.002%, is added as a preservative.

It is a nonviscous liquid, buffered at pH 5, for instillation into the canal of the external ear or direct application to the affected aural skin. The structural formulas of colistin sulfate (mixture of Colistin A & B), neomycin sulfate (mixture of neomycin A, B & C), hydrocortisone acetate ((11β)-21-(acetyloxy)-11,17-dihydroxypregn) methyl]-2 pyrimidinylamino] ethyl]-N,N-dimethyl-1-hexadecanaminium, bromide) are represented below: Thonzonium Bromide Colistin sulfate Neomycin A Neomycin B Sulfate Hydrocortisone Acetate Neomycin C Sulfate Thonzonium Bromide Colistin Sulfate Neomycin A Neomycin B Sulfate Hydrocortisone Acetate Neomycin C Sulfate

💬 Information for Patients 77 words

Information for Patients Avoid contaminating the dropper with material from the ear, fingers, or other source. This caution is necessary if the sterility of the drops is to be preserved. If sensitization or irritation occurs, discontinue use immediately and contact your physician.

Do not use in the eyes. If you prefer to warm the medication before using it, do not heat the suspension above body temperature in order to avoid loss of potency. SHAKE WELL BEFORE USING.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.